NASDAQ:CRSP CRISPR Therapeutics Q4 2025 Earnings Report $56.56 -0.77 (-1.34%) Closing price 04:00 PM EasternExtended Trading$57.46 +0.89 (+1.58%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast CRISPR Therapeutics EPS ResultsActual EPS-$1.37Consensus EPS -$1.15Beat/MissMissed by -$0.22One Year Ago EPS-$1.01CRISPR Therapeutics Revenue ResultsActual Revenue$0.86 millionExpected Revenue$4.72 millionBeat/MissMissed by -$3.86 millionYoY Revenue Growth-97.80%CRISPR Therapeutics Announcement DetailsQuarterQ4 2025Date2/13/2026TimeBefore Market OpensConference Call DateThursday, February 12, 2026Conference Call Time4:00PM ETUpcoming EarningsCRISPR Therapeutics' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 3, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) CRISPR Therapeutics Earnings HeadlinesIn Vivo Gene Editing Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)September 18 at 12:03 PM | finance.yahoo.comWhere Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?September 17 at 11:00 PM | fool.comWhitney Tilson: “A New Kind of Civil War Begins in Less Than 100 Days”President Trump says AI regulation will not stop what he calls the greatest economic engine in history, bigger than oil, gold, diamonds, or the internet. Meanwhile, The New Republic reports Republicans are eager to rein in AI ahead of the midterms. Whitney Tilson, the analyst CNBC once called The Prophet for calling the dot-com crash, the Bear Stearns and Lehman collapses, and the 2009 market bottom, says a new divide begins in 100 days with major implications for portfolios. Tilson lays out what he believes could separate winning and losing portfolios over the next six months.September 18 at 1:00 AM | Stansberry Research (Ad)Gene-Editing Powerhouse And Its Rivals Surge Toward A BreakoutSeptember 17 at 8:51 PM | finance.yahoo.comWall Street Analysts Think CRISPR Therapeutics (CRSP) Is a Good Investment: Is It?September 17 at 10:50 AM | finance.yahoo.comCRISPR Therapeutics (CRSP) Gains Attention As CASGEVY Momentum Builds But Is The Valuation Too RichSeptember 16 at 12:54 PM | finance.yahoo.comSee More CRISPR Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CRISPR Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CRISPR Therapeutics and other key companies, straight to your email. Email Address About CRISPR TherapeuticsCRISPR Therapeutics (NASDAQ:CRSP) (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines using CRISPR/Cas9 technology. The company’s programs are designed to modify disease-associated genes in human cells, with the goal of treating serious conditions across hematology, oncology, autoimmune disease and regenerative medicine. Its most advanced product is Casgevy (exa-cel), an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals. Casgevy uses CRISPR/Cas9 gene editing to modify a patient’s blood stem cells and is approved in several markets for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. The product was among the first medicines based on CRISPR gene-editing technology to receive regulatory approval. Founded in 2013, CRISPR Therapeutics operates internationally, with corporate activities in Switzerland and the United States. In addition to its hemoglobinopathy program, the company is advancing investigational therapies in areas such as cancer, type 1 diabetes and immune-mediated diseases through both internal research and collaborations. Its scientific origins are associated with CRISPR pioneers Emmanuelle Charpentier and Rodger Novak, while Samarth Kulkarni has served as the company’s chief executive officer.View CRISPR Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and ScaleMicron’s New 512GB Memory Module Deepens Its AI Infrastructure AdvantageThese 3 Stocks Are Drawing Insider Buyers for Very Different Reasons Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
